The Oncology Institute, Inc. (NASDAQ:TOI - Get Free Report) Director Brad Hively sold 1,976,137 shares of the firm's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $2.87, for a total transaction of $5,671,513.19. Following the completion of the transaction, the director now directly owns 603,501 shares in the company, valued at $1,732,047.87. This represents a 76.61% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Oncology Institute Stock Down 0.4%
Shares of Oncology Institute stock traded down $0.01 on Friday, hitting $2.78. 1,364,431 shares of the company traded hands, compared to its average volume of 994,651. The company has a 50-day moving average price of $2.52 and a 200 day moving average price of $1.27. The company has a quick ratio of 2.27, a current ratio of 2.49 and a debt-to-equity ratio of 5.91. The Oncology Institute, Inc. has a 12-month low of $0.13 and a 12-month high of $3.50. The company has a market cap of $248.07 million, a PE ratio of -3.56 and a beta of 0.13.
Oncology Institute (NASDAQ:TOI - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.18) earnings per share for the quarter. The firm had revenue of $104.41 million for the quarter. Oncology Institute had a negative return on equity of 186.83% and a negative net margin of 17.63%.
Institutional Investors Weigh In On Oncology Institute
Large investors have recently bought and sold shares of the business. Josh Arnold Investment Consultant LLC acquired a new position in Oncology Institute during the 1st quarter worth $2,267,000. FreeGulliver LLC lifted its holdings in Oncology Institute by 219.3% during the 4th quarter. FreeGulliver LLC now owns 600,747 shares of the company's stock worth $186,000 after buying an additional 412,578 shares in the last quarter. Tiff Advisory Services LLC lifted its holdings in Oncology Institute by 13.2% during the 4th quarter. Tiff Advisory Services LLC now owns 2,979,141 shares of the company's stock worth $921,000 after buying an additional 346,256 shares in the last quarter. Virtu Financial LLC acquired a new position in Oncology Institute during the 4th quarter worth $41,000. Finally, Goldman Sachs Group Inc. acquired a new position in Oncology Institute during the 1st quarter worth $131,000. 36.86% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Separately, BTIG Research assumed coverage on Oncology Institute in a report on Thursday, May 15th. They set a "buy" rating and a $7.00 target price on the stock.
Check Out Our Latest Report on TOI
Oncology Institute Company Profile
(
Get Free Report)
The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.
See Also
Before you consider Oncology Institute, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncology Institute wasn't on the list.
While Oncology Institute currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
